An interventional study of Questionnaire in Hypertension and Renal Insufficiency, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 211 studies in Hypertension with a site in France — 33 open to participants now, 46 under way, 6 of them phase 3. Hypertension · France.
Among the 211 studies in Hypertension with a site in France, this one is the 108th largest by planned enrollment of the 152 interventional ones that give a count, is one of 17 that started in 2023, is one of 62 with no phase, reaches primary completion later than 16 of the 45 other live ones, and was the 172nd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →33 of the 211 studies in Hypertension with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 18+
Centre Hospitalier de PAU · Sites in France
Ages 18+
University of Poitiers · Sites in France
Ages 18–45 · Women only · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
211 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 17 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99 is close to the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 272 across the 152 interventional studies, 400 across the 59 observational. Of the 144 that completed or were terminated, 41 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 211 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 4 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
8 of the studies in Hypertension with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2027-01 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT06559891SoniVie Inc.THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension | 2027-03-31 |
| NCT05917600Assistance Publique - Hôpitaux de ParisImpact of Advanced Practical Nursing Intervention Versus Usual Care on Hypertension Control | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 211 studies in Hypertension with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
EvalSel can precisely assess the salt intake of hospitalized patients in nephrology and cardiology or in medical consultation. It can determine salt consumption to the nearest gram.
The objectives of this food frequency questionnaire are to arrive at a precise dietary diagnosis and to quickly identify the dietary errors made by the patients.
EvalSel is useful for doctors to quickly obtain an assessment of the salt consumption of their patients, so they can refer them to dietitians if necessary. It can be used on the day of admission to hospital or during medical follow-ups to know the evolution of their consumption over the long term and improve their care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients with high blood pressure or chronic kidney diseases stages 4-5
Other: Questionnaire
These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
Intra-class correlation coefficient between the quantitative measurement of sodium consumption and the 24-hour natriuresis measurement and verification of the 24-hour creatininuria values
Intra-class correlation coefficient between the quantitative measurement of sodium consumption by the EvalSel questionnaire and the 24-hour natriuresis measurement (amount of sodium in 24-hour urine) and verification of the 24-hour creatininuria values (amount of creatinine in 24-hour urine) to confirm that the urine collection was performed correctly.
Time frame: through study completion an average of 18 months
Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 36 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.